TaiMed Biologics (4147) fair value: what the stock is really worth
As of Oct 28, 2026: fair value (intrinsic value) of TaiMed Biologics stock TWD 13.48, price TWD 60.30, upside -77.6%, quality 60 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Oct 27, 2026.
How to read this chart
60‑month range 47.10 TWD – 132.00 TWD · fair‑value band 8.45 TWD – 20.02 TWD · the 60.30 TWD price screens above the 13.48 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Oct 27, 2026.
Follow TaiMed Biologics in your weekly email
Every Wednesday you see whether TaiMed Biologics is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment.
Show moreShow less
It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment.
In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355.
TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
Stock analysis
TaiMed Biologics (4147) currently trades at 60.30 TWD, while our model-based Fair Value estimate is 13.48 TWD, 77.6% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of 13.48 TWD per share, and 0 of the 7 models we run sit above the 60.30 TWD price.
Bear case: the Multiples group reads lowest at 5.04 TWD, and 7 of the 7 models stay below the price. Data coverage for this calculation is low.
Scenario range: 8.45 TWD (bear) to 20.02 TWD (bull), the price of 60.30 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Healthcare sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
TaiMed Biologics reported revenue of 611M TWD in FY2025 versus 413M TWD in FY2021, a compound +10.3%/yr. Reported net income was −168M TWD in FY2025.
Key figures
Market cap 16.5B TWD (≈ $506M) Small · P/S ratio 26.8 · EPS (TTM) −0.5100 TWD · Net margin −22.4% · Return on equity −3.7% · Return on assets (EBIT) −5.7% · Operating margin −47.9% · Revenue (TTM) 619M TWD.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 12 out of 100 (low confidence).
What moves the price
The share trades about 17% below its 52-week high and 28% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 3% fair-value upside, at −78%, 4147 screens richer than that median.
Fair Value models
Bear8.45 TWDFair Value 13.48 TWDBull20.02 TWD
Price 60.30 TWD · Upside -77.6%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.21/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+0.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+2.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.3%
Start year 2020 (pandemic)
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+69.1%
’10
’11
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−18.4% (2020) → −31.8% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+46.6%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (Taiwan: IMF forecast 1.6% a year to 2030, 1.5% from 2016 to 2025) that is about +44.3% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 599 stocks
Beats the industry median on 3/10 measures
Overall it trails its industry peers.
Valuation
Quality Score60 · Top 25%
Fair Value upside−77.6% · Bottom 25%
Profitability
Return on assets−3.5% · Above median
Net margin (12 months)−22.4% · Below median
Operating margin (12 months)−47.9% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY)13.3% · Above median
Balance sheet
Debt / equity0.11× · Above median
Valuation Multiplesvs Biotechnology median · lower = cheaper
P/B4.27× · Priciest 25%
P/S (12 months)26.59× · Priciest 25%
Price / free cash flow97.8× · Priciest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)67· sector 0
PAST (return on equity)0· sector 0
HEALTH (low debt)94· sector 97
DIVIDEND (yield)0· sector 24
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "TaiMed Biologics Fair Value". https://www.fairvalue-calculator.com/stock/4147
Frequently asked questions
Is TaiMed Biologics (4147) overvalued or undervalued?
As of Oct 27, 2026, our model estimates a fair value of 13.48 TWD versus a price of 60.30 TWD, about −78% upside (overvalued).
What is the fair value of 4147?
Our model-based fair value for TaiMed Biologics is 13.48 TWD (as of Oct 27, 2026), built from audited fundamentals. The current price: 60.30 TWD.
What is the quality score of 4147?
TaiMed Biologics has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for TaiMed Biologics (4147)?
Our model-based price target is the fair value of 13.48 TWD (as of Oct 27, 2026) from 7 valuation models. Cautious scenario 8.45 TWD, optimistic scenario 20.02 TWD. It is a calculation from audited fundamentals, not an analyst target.
What is the TaiMed Biologics stock forecast for 2026?
Our models put fair value at 13.48 TWD, about −78% upside versus a price of 60.30 TWD (overvalued). Cautious scenario 8.45 TWD, optimistic scenario 20.02 TWD. The calculation is refreshed regularly with new filings.
What is the revenue of TaiMed Biologics (4147)?
TaiMed Biologics reported trailing-twelve-month revenue of about 619M TWD (latest available figure, as of Oct 27, 2026).
What growth is priced into TaiMed Biologics (4147)?
For today's price to be fair in a discounted-cash-flow model, TaiMed Biologics would have to grow free cash flow by +46.6 % per year for five years (discount rate 11.8 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -3.3 % per year. As of Oct 27, 2026.
What discount rate (WACC) does the fair value of 4147 use?
Our models discount TaiMed Biologics at 11.8 %: a base by market capitalisation (small), country premium for Taiwan. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For TaiMed Biologics that is +46.6 % per year a year over ten years, using the same discount rate (11.8 %) and the same formula as our fair value.
How much growth has TaiMed Biologics (4147) delivered so far?
Over the past 5 years revenue at TaiMed Biologics grew -3.3 % a year. The price currently implies +46.6 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of TaiMed Biologics (4147) growing?
The median revenue growth in the sector is +6.1 % a year. That is the yardstick for the growth priced into TaiMed Biologics (+46.6 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of TaiMed Biologics (4147)?
The free-cash-flow yield on the price is 1.02 %: that much free cash flow TaiMed Biologics produces per unit of market value. When it exceeds the discount rate of our models (11.8 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of TaiMed Biologics (4147)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For TaiMed Biologics it is 13.48 TWD per share (as of Oct 27, 2026), against a price of 60.30 TWD. It is the blended result of 7 valuation models (cash flow, earnings, asset, dividend).
Is TaiMed Biologics stock overvalued or undervalued in 2026?
As of Oct 27, 2026, 4147 trades above its calculated fair value: price 60.30 TWD, fair value 13.48 TWD, a gap of about −78% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 4147?
No. The price is what the market pays today (60.30 TWD); the fair value is what the company's own numbers justify (13.48 TWD). For TaiMed Biologics the two are 46.82 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is TaiMed Biologics worth?
The market values TaiMed Biologics at about 16.5B TWD (market capitalisation, as of Oct 27, 2026). Per share that is 60.30 TWD; our models calculate a fair value of 13.48 TWD per share.
What do the bullish and bearish scenarios say about 4147?
Our models span a range for TaiMed Biologics: cautious scenario 8.45 TWD, base 13.48 TWD, optimistic 20.02 TWD per share (as of Oct 27, 2026, price 60.30 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of TaiMed Biologics (4147)?
Balance-sheet figures for TaiMed Biologics (as of Oct 27, 2026): return on equity −3.7%, debt of 0.11 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 4147 from its 52-week high?
TaiMed Biologics trades at 60.30 TWD, about 17% below its 52-week high of 72.60 TWD and 28% above the low of 47.10 TWD (as of Oct 28, 2026). Distance from the high says nothing about value: that is what the fair value of 13.48 TWD is for.
Which stocks are comparable to TaiMed Biologics?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, CSL Limited, argenx SE, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is TaiMed Biologics stock attractive at the current price?
The data as of Oct 27, 2026: price 60.30 TWD, calculated fair value 13.48 TWD (−78%), Quality Score 60/100, from 7 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 4147 calculated?
We run TaiMed Biologics through 7 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 13.48 TWD, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. TaiMed Biologics itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of TaiMed Biologics (4147)?
The closing price on Oct 28, 2026 was 60.30 TWD. Our model-based fair value is 13.48 TWD, about −78% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with TaiMed Biologics right now?
The price sits above even our optimistic bull case (20.02 TWD). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (60/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (8.45 TWD to 20.02 TWD) leaves room in how you read the outcome.
Key figures of TaiMed Biologics
How large is the market capitalisation of TaiMed Biologics (4147)?
The market capitalisation of TaiMed Biologics is 16.5B TWD (≈ $506M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of TaiMed Biologics (4147)?
The price-to-sales ratio of TaiMed Biologics is 26.8 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of TaiMed Biologics (4147)?
Earnings per share at TaiMed Biologics are −0.5100 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the net margin of TaiMed Biologics (4147)?
The net margin of TaiMed Biologics is −22.4% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of TaiMed Biologics (4147)?
The return on equity (ROE) of TaiMed Biologics is −3.7% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of TaiMed Biologics (4147)?
On an EBIT basis the return on assets of TaiMed Biologics is −5.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of TaiMed Biologics (4147)?
The operating margin of TaiMed Biologics is −47.9% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at TaiMed Biologics (4147)?
Revenue at TaiMed Biologics is growing +13.3% versus a year earlier (3y avg +2.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much net debt does TaiMed Biologics (4147) carry?
The net debt of TaiMed Biologics is 471M TWD (fiscal year 2023, ≈ 2.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch TaiMed Biologics in the live analysis
One click puts TaiMed Biologics on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 27, 2026